Linking EMT Status of Circulating Tumor Cells to Clinical Outcomes in Lung Cancer

References

• Huang S, Yang J, Shen N, Xu Q, Zhao Q. Artificial intelligence in lung cancer diagnosis and prognosis: current application and future perspective. Semin Cancer Biol. 2023;89:30–37. doi:10.1016/j.semcancer.2023.01.006
   PubMed Web of Science ®Google Scholar
• Cao M, Li H, Sun D, et al. Cancer screening in China: the current status, challenges, and suggestions. Cancer Lett. 2021;506:120–127. doi:10.1016/j.canlet.2021.02.017
   PubMed Web of Science ®Google Scholar
• Dalmartello M, La Vecchia C, Bertuccio P, et al. European cancer mortality predictions for the year 2022 with focus on ovarian cancer. Ann Oncol. 2022;33(3):330–339. doi:10.1016/j.annonc.2021.12.007
   PubMed Web of Science ®Google Scholar
• Lewis DR, Siembida EJ, Seibel NL, Smith AW, Mariotto AB. Survival outcomes for cancer types with the highest death rates for adolescents and young adults, 1975–2016. Cancer. 2021;127(22):4277–4286. doi:10.1002/cncr.33793
   PubMed Web of Science ®Google Scholar
• Rudin CM, Brambilla E, Faivre-Finn C, Sage J. Small-cell lung cancer. Nat Rev Dis Primers. 2021;7(1):3. doi:10.1038/s41572-020-00235-0
   PubMed Web of Science ®Google Scholar
• Ko J, Winslow MM, Sage J. Mechanisms of small cell lung cancer metastasis. EMBO Mol Med. 2021;13(1):e13122. doi:10.15252/emmm.202013122
   PubMed Web of Science ®Google Scholar
• Kang J, Zhang C, Zhong WZ. Neoadjuvant immunotherapy for non-small cell lung cancer: state of the art. Cancer Commun. 2021;41(4):287–302. doi:10.1002/cac2.12153
   PubMed Web of Science ®Google Scholar
• Park HA, Brown SR, Kim Y. Cellular mechanisms of circulating tumor cells during breast cancer metastasis. Int J Mol Sci. 2020;21(14):5040. doi:10.3390/ijms21145040
   PubMed Web of Science ®Google Scholar
• Pei H, Li L, Han Z, Wang Y, Tang B. Recent advances in microfluidic technologies for circulating tumor cells: enrichment, single-cell analysis, and liquid biopsy for clinical applications. Lab Chip. 2020;20(21):3854–3875. doi:10.1039/d0lc00577k
   PubMed Web of Science ®Google Scholar
• Tinganelli W, Durante M. Tumor hypoxia and circulating tumor cells. Int J Mol Sci. 2020;21(24):9592. doi:10.3390/ijms21249592
   PubMed Web of Science ®Google Scholar
• Yousefi M, Ghaffari P, Nosrati R, et al. Prognostic and therapeutic significance of circulating tumor cells in patients with lung cancer. Cell Oncol. 2020;43(1):31–49. doi:10.1007/s13402-019-00470-y
   PubMed Web of Science ®Google Scholar
• Huang Y, Hong W, Wei X. The molecular mechanisms and therapeutic strategies of EMT in tumor progression and metastasis. J Hematol Oncol. 2022;15(1):129. doi:10.1186/s13045-022-01347-8
   PubMed Web of Science ®Google Scholar
• Ebrahimi N, Adelian S, Shakerian S, et al. Crosstalk between ferroptosis and the epithelial-mesenchymal transition: implications for inflammation and cancer therapy. Cytokine Growth Factor Rev. 2022;64:33–45. doi:10.1016/j.cytogfr.2022.01.006
   PubMed Web of Science ®Google Scholar
• Zhang Q, Rong Y, Yi K, Huang L, Chen M, Wang F. Circulating tumor cells in hepatocellular carcinoma: single-cell based analysis, preclinical models, and clinical applications. Theranostics. 2020;10(26):12060–12071. doi:10.7150/thno.48918
   PubMed Web of Science ®Google Scholar
• Li J, Liao Y, Ran Y, et al. Evaluation of sensitivity and specificity of CanPatrol™ technology for detection of circulating tumor cells in patients with non-small cell lung cancer. BMC Pulm Med. 2020;20(1):274. doi:10.1186/s12890-020-01314-4
   PubMed Web of Science ®Google Scholar
• Chen J, Ye C, Dong J, et al. Metabolic classification of circulating tumor cells as a biomarker for metastasis and prognosis in breast cancer. J Transl Med. 2020;18(1):59. doi:10.1186/s12967-020-02237-8
   PubMed Web of Science ®Google Scholar
• Goldstraw P, Chansky K, Crowley J, et al. The IASLC Lung Cancer Staging Project: proposals for Revision of the TNM Stage Groupings in the Forthcoming (Eighth) Edition of the TNM Classification for Lung Cancer. J Thorac Oncol. 2016;11(1):39–51. doi:10.1016/j.jtho.2015.09.009
   PubMed Web of Science ®Google Scholar
• Qi LN, Xiang BD, Wu FX, et al. Circulating tumor cells undergoing EMT provide a metric for diagnosis and prognosis of patients with hepatocellular carcinoma. Cancer Res. 2018;78(16):4731–4744. doi:10.1158/0008-5472.CAN-17-2459
   PubMed Web of Science ®Google Scholar
• Asante DB, Morici M, Mohan GRKA, et al. Multi-marker immunofluorescent staining and PD-L1 detection on circulating tumour cells from ovarian cancer patients. Cancers. 2021;13(24):6225. doi:10.3390/cancers13246225
   PubMed Web of Science ®Google Scholar
• Eisenhauer EA, Therasse P, Bogaerts J, et al. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer. 2009;45(2):228–247. doi:10.1016/j.ejca.2008.10.026
   PubMed Web of Science ®Google Scholar
• De Souza LM, Robertson BM, Robertson GP. Future of circulating tumor cells in the melanoma clinical and research laboratory settings. Cancer Lett. 2017;392:60–70. doi:10.1016/j.canlet.2017.01.023
   PubMed Web of Science ®Google Scholar
• Teeuwssen M, Fodde R. Cell heterogeneity and phenotypic plasticity in metastasis formation: the case of colon cancer [published correction appears in Cancers (Basel). 2020 May 28;12(6)]. Cancers. 2019;11(9):1368. doi:10.3390/cancers11091368
   PubMed Web of Science ®Google Scholar
• Thiery JP, Lim CT. Tumor dissemination: an EMT affair. Cancer Cell. 2013;23(3):272–273. doi:10.1016/j.ccr.2013.03.004
   PubMed Web of Science ®Google Scholar
• Brabletz S, Schuhwerk H, Brabletz T, Stemmler MP. Dynamic EMT: a multi-tool for tumor progression. EMBO J. 2021;40(18):e108647. doi:10.15252/embj.2021108647
   PubMed Web of Science ®Google Scholar
• Pantazaka E, Vardas V, Roumeliotou A, Kakavogiannis S, Kallergi G. Clinical relevance of mesenchymal- and stem-associated phenotypes in circulating tumor cells isolated from lung cancer patients. Cancers. 2021;13(9):2158. doi:10.3390/cancers13092158
   PubMed Web of Science ®Google Scholar
• Li D, Xia L, Huang P, et al. Heterogeneity and plasticity of epithelial-mesenchymal transition (EMT) in cancer metastasis: focusing on partial EMT and regulatory mechanisms. Cell Prolif. 2023;56(6):e13423. doi:10.1111/cpr.13423
   PubMed Web of Science ®Google Scholar
• Nihan Kilinc A, Sugiyama N, Reddy Kalathur RK, et al. Histone deacetylases, Mbd3/NuRD, and Tet2 hydroxylase are crucial regulators of epithelial-mesenchymal plasticity and tumor metastasis. Oncogene. 2020;39(7):1498–1513. doi:10.1038/s41388-019-1081-2
   PubMed Web of Science ®Google Scholar
• Riggio AI, Varley KE, Welm AL. The lingering mysteries of metastatic recurrence in breast cancer. Br J Cancer. 2021;124(1):13–26. doi:10.1038/s41416-020-01161-4
   PubMed Web of Science ®Google Scholar
• Semaan A, Bernard V, Kim DU, et al. Characterisation of circulating tumour cell phenotypes identifies a partial-EMT sub-population for clinical stratification of pancreatic cancer. Br J Cancer. 2021;124(12):1970–1977. doi:10.1038/s41416-021-01350-9
   PubMed Web of Science ®Google Scholar
• Tada H, Takahashi H, Ida S, Nagata Y, Chikamatsu K. Epithelial-mesenchymal transition status of circulating tumor cells is associated with tumor relapse in head and neck squamous cell carcinoma. Anticancer Res. 2020;40(6):3559–3564. doi:10.21873/anticanres.14345
   PubMed Web of Science ®Google Scholar
• Manjunath Y, Upparahalli SV, Avella DM, et al. PD-L1 expression with epithelial mesenchymal transition of circulating tumor cells is associated with poor survival in curatively resected non-small cell lung cancer. Cancers. 2019;11(6):806. doi:10.3390/cancers11060806
   PubMed Web of Science ®Google Scholar
• Zhang Y, Men Y, Wang J, et al. Epithelial circulating tumor cells with a heterogeneous phenotype are associated with metastasis in NSCLC. J Cancer Res Clin Oncol. 2022;148(5):1137–1146. doi:10.1007/s00432-021-03681-9
   PubMed Web of Science ®Google Scholar